Screening for conditions that do not meet the Wilson and Jungner criteria: The case of Duchenne muscular dystrophy

No abstract is available for this paper.

• Publication year

  2006

• Venue

  American Journal of Medical Genetics. Part A

• Publication date

  2006-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajmg.a.31165PMID 16528755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ethical issues with genetic testing in pediatrics.

  2013cited by this paper
• Principles and Implications

  2008cited by this paper
• Testing Children and Adolescents

  2008cited by this paper
• Practice parameter: Corticosteroid treatment of Duchenne dystrophy - Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society

  2006cited by this paper
• Pediatricians' Attitudes Toward Expanding Newborn Screening

  2005cited by this paper
• Parental Attitudes and Beliefs regarding the Genetic Testing of Children

  2005cited by this paper
• Children in the United States with discontinuous health insurance coverage.

  2005cited by this paper
• A symptomatic female patient with Duchenne muscular dystrophy diagnosed by dystrophin-staining: A case report

  2005cited by this paper
• Compliance With National Immunization Guidelines for Children Younger Than 2 Years, 1996-1999

  2005cited by this paper
• Newborn screening for developmental disabilities: reframing presumptive benefit.

  2005cited by this paper
• Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands.

  2004cited by this paper
• Recent advances in newborn screening for neurometabolic disorders

  2004cited by this paper
• Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review.

  2004cited by this paper
• Incorporating newborn screening into prenatal care.

  2004cited by this paper
• Developmental progress in Duchenne muscular dystrophy: lessons for earlier detection.

  2004cited by this paper
• The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use.

  2003cited by this paper
• Parental attitudes regarding newborn screening of PKU and DMD

  2003cited by this paper
• Expanded newborn screening using tandem mass spectrometry.

  2003cited by this paper
• Dystrophin and mutations: one gene, several proteins, multiple phenotypes.

  2003cited by this paper
• Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies.

  2003cited by this paper
• Minimizing risks: the ethics of predictive diabetes mellitus screening research in newborns.

  2003cited by this paper
• Predictive Genetic Testing for Conditions that Present in Childhood

  2002influential reference
• Report on the muscular dystrophy campaign workshop: exercise in neuromuscular diseases Newcastle, January 2002.

  2002cited by this paper
• Screening for cardiovascular risk: public health imperative or matter for individual informed choice?

  2002cited by this paper
• Corticosteroids in Duchenne Muscular Dystrophy: A Reappraisal

  2002cited by this paper
• Newborn screening for Duchenne muscular dystrophy: a psychosocial study

  2002cited by this paper
• Pseudo-metabolic presentation in a Duchenne muscular dystrophy symptomatic carrier with 'de novo' duplication of dystrophin gene.

  2001cited by this paper
• Carrier detection and prenatal molecular diagnosis in a Duchenne muscular dystrophy family without any affected relative available.

  2001cited by this paper
• U.S. newborn screening policy dilemmas for the twenty-first century.

  2001cited by this paper
• Information about screening – is it to achieve high uptake or to ensure informed choice?

  2001cited by this paper
• Cardiac abnormalities and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and controls.

  2001cited by this paper
• The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish Type 1 Diabetes Prediction and Prevention Study.

  2001cited by this paper
• Sickle cell.

  2001cited by this paper
• False-negative results in screening programmes: systematic review of impact and implications.

  2000cited by this paper
• Use of Inhaled Nitric Oxide

  2000cited by this paper
• Primum Non Nocere and the Quality of Evidence: Rethinking the Ethics of Screening

  2000cited by this paper
• Feasibility of a Change in Service Delivery: The Case of Optional Newborn Screening for Duchenne Muscular Dystrophy

  2000cited by this paper
• Serving the family from birth to the medical home. A report from the Newborn Screening Task Force convened in Washington DC, May 10-11, 1999.

  2000cited by this paper
• Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study.

  1999cited by this paper
• Failure of early diagnosis in symptomatic Duchenne muscular dystrophy.

  1999influential reference
• Prevention of type 1 diabetes from laboratory to public health.

  1999cited by this paper
• DNA analysis of Huntington’s disease

  1999cited by this paper
• Principles and performance: assessing the evidence

  1999cited by this paper
• Medical screening and the value of early detection. When unwarranted faith leads to unethical recommendations.

  1999cited by this paper
• Newborn screening for Duchenne muscular dystrophy

  1998cited by this paper
• The Genetic Testing of Children

  1998cited by this paper
• Neonatal Screening for Duchenne Muscular Dystrophy: A Novel Semiquantitative Application of the Bioluminescence Test for Creatine Kinase in a Pilot National Program in Cyprus

  1998influential reference
• Absence of correlation between skewed X inactivation in blood and serum creatine-kinase levels in Duchenne/Becker female carriers.

  1998cited by this paper
• Reactions to the threatened loss of a child: a vulnerable child syndrome, by Morris Green, MD, and Albert A. Solnit, MD, Pediatrics, 1964;34:58-66.

  1998cited by this paper
• Genetic Secrets: Protecting Privacy and Confidentiality in the Genetic Era

  1998cited by this paper
• Genetic screening and public health.

  1997cited by this paper
• Parental attitudes to genetic counseling and predictive testing for childhood cancer.

  1996cited by this paper
• Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies.

  1996cited by this paper
• From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group.

  1996cited by this paper
• Attitudes of 47 mothers of pediatric oncology patients toward genetic testing for cancer predisposition.

  1996cited by this paper
• Parents' responses to predictive genetic testing in their children: report of a single case study.

  1996cited by this paper
• Genetic counseling of isolated carriers of Duchenne muscular dystrophy.

  1996cited by this paper
• GIG response to the UK Clinical Genetics Society report "The genetic testing of children".

  1995cited by this paper
• A carrier of Duchenne muscular dystrophy with dilated cardiomyopathy but no skeletal muscle symptom.

  1995cited by this paper
• No improvement in delay in diagnosis of Duchenne muscular dystrophy.

  1995cited by this paper
• Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors.

  1995cited by this paper
• Psychosocial effects of screening for disease prevention and detection

  1995cited by this paper
• The genetic testing of children. Working Party of the Clinical Genetics Society (UK)

  1994cited by this paper
• Assessing Genetic Risks: Implications for Health and Social Policy

  1994cited by this paper
• Uptake of cystic fibrosis testing in primary care: supply push or demand pull?

  1993cited by this paper
• Experience with screening newborns for Duchenne muscular dystrophy in Wales.

  1993influential reference
• What counts as success in genetic counselling?

  1993cited by this paper
• Impact of genetic counselling after neonatal screening for Duchenne muscular dystrophy.

  1993influential reference
• Neonatal screening for muscular dystrophy. Consensus recommendation of the 14th workshop sponsored by the European Neuromuscular Center (ENMC).

  1993influential reference
• Canadian experience with predictive testing for Huntington disease: lessons for genetic testing centers and policy makers.

  1992cited by this paper
• Neonatal screening for Duchenne/Becker muscular dystrophy; Reconsideration based on molecular diagnosis and potential therapeutics

  1992cited by this paper
• First report

  1992cited by this paper
• Three years' experience with neonatal screening for Duchenne/Becker muscular dystrophy: gene analysis, gene expression, and phenotype prediction.

  1991cited by this paper
• Dangerous Diagnostics: The Social Power of Biological Information

  1990cited by this paper
• VENTILATOR USE IN PROGRESSIVE NEUROMUSCULAR DISEASE: IMPACT ON PATIENTS AND THEIR FAMILIES

  1988cited by this paper
• [Systematic neonatal detection of Duchenne's muscular dystrophy. Results after 10 years' of experience in Lyons (France)].

  1987cited by this paper
• Screening for Cystic Fibrosis

  1987cited by this paper
• Screening for duchenne muscular dystrophy: An improved screening test for creatine kinase and its application in an infant screening program

  1986cited by this paper
• Genetic screening: marvel or menace?

  1984cited by this paper
• A rapid screening test for Duchenne muscular dystrophy using dried blood specimens.

  1984cited by this paper
• Implications of diagnostic delay in Duchenne muscular dystrophy.

  1983cited by this paper
• Diagnostic delay in Duchenne's muscular dystrophy.

  1982influential reference
• Feasibility of neonatal screening for Duchenne muscular dystrophy.

  1982cited by this paper
• Carrier detection in Duchenne muscular dystrophy: Assessment of the effect of age on detection-rate with serum-creatine-kinase-activity.

  1979cited by this paper
• Genetics, Law, and Social Policy

  1978cited by this paper
• Muscular dystrophy screening.

  1978cited by this paper
• GENETIC SCREENING: PROGRAMS, PRINCIPLES AND RESEARCH

  1976cited by this paper
• Serum creatine phosphokinase in normal newborns.

  1976cited by this paper
• TREATMENT OF SMALL-CELL CARCINOMA OF BRONCHUS

  1975cited by this paper
• Newborn screening for Duchenne muscular dystrophy.

  1975influential reference
• FOLLOW-UP STUDY OF SERUM-CREATINE-KINASE IN CARRIERS OF DUCHENNE MUSCULAR DYSTROPHY

  1974cited by this paper
• REACTIONS TO THE THREATENED LOSS OF A CHILD: A VULNERABLE CHILD SYNDROME. PEDIATRIC MANAGEMENT OF THE DYING CHILD, PART III.

  1964cited by this paper

• Wilson and Jungner Revisited: Are Screening Criteria Fit for the 21st Century?

  2024cites this paper
• Newborn screening for Duchenne muscular dystrophy: the perspectives of stakeholders

  2024cites this paper
• The case for screening in early life for ‘non-treatable’ disorders: ethics, evidence and proportionality. A report from the Health Council of the Netherlands

  2022influential citation
• “We needed this”: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy

  2021cites this paper
• Measurement of Reverse Triiodothyronine Level and the Triiodothyronine to Reverse Triiodothyronine Ratio in Dried Blood Spot Samples at Birth May Facilitate Early Detection of Monocarboxylate Transporter 8 Deficiency

  2021cites this paper
• Utility of Gene Panels for the Diagnosis of Inborn Errors of Metabolism in a Metabolic Reference Center

  2021cites this paper
• Opinions of adults affected with later‐onset lysosomal storage diseases regarding newborn screening: A qualitative study

  2021cites this paper
• Frontline Ethico-Legal Issues in Childhood Cancer Genetics Research

  2021cites this paper
• Population Health Screening after Environmental Pollution

  2020cites this paper
• Early developmental milestones in Duchenne muscular dystrophy

  2020cites this paper
• Metabolomics to Improve the Diagnostic Efficiency of Inborn Errors of Metabolism

  2020cites this paper
• What is in a Name? Parent, Professional and Policy-Maker Conceptions of Consent-Related Language in the Context of Newborn Screening

  2019cites this paper
• Spinal Muscular Atrophy: Past, Present, and Future.

  2019cites this paper
• What are the goals of prenatal genetic testing?

  2018cites this paper
• Ethics in genetic counselling

  2018cites this paper
• CUGC for Duchenne muscular dystrophy (DMD)

  2018cites this paper
• Clinical Utility Gene Card for: Becker muscular dystrophy

  2018cites this paper
• Fostering caring relationships: Suggestions to rethink liberal perspectives on the ethics of newborn screening

  2018cites this paper
• Indifferent or Uninformed? Reflections of Health Professionals on Parental Education and Consent for Expanded Newborn Screening in Israel, 2008–2016

  2017cites this paper
• A comparative study of care practices for young boys with Duchenne muscular dystrophy between Japan and European countries: Implications of early diagnosis.

  2016cites this paper
• Clinical Follow‐Up for Duchenne Muscular Dystrophy Newborn Screening: A Proposal

  2016cites this paper
• Ethical and policy issues in newborn screening of children for neurologic and developmental disorders.

  2015cites this paper
• Framing optional genetic testing in the context of mandatory newborn screening tests

  2015cites this paper
• Applying Public Health Screening Criteria: How Does Universal Newborn Screening Compare to Universal Tumor Screening for Lynch Syndrome in Adults with Colorectal Cancer?

  2015cites this paper
• A mixed methods study of age at diagnosis and diagnostic odyssey for Duchenne muscular dystrophy

  2015cites this paper
• Screening for Klinefelter syndrome

  2015cites this paper
• Cystic fibrosis newborn screening: A model for neuromuscular disease screening?

  2015cites this paper
• Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe

  2014cites this paper
• Parental attitudes toward newborn screening for Duchenne/Becker muscular dystrophy and spinal muscular atrophy

  2014cites this paper
• A mixed methods exploration of families’ experiences of the diagnosis of childhood spinal muscular atrophy

  2014cites this paper
• Parental perspectives on the diagnostic process for Duchenne and Becker muscular dystrophy

  2013cites this paper
• The new genetics and informed consent: differentiating choice to preserve autonomy.

  2013cites this paper
• The ‘thousand-dollar genome’: an ethical exploration

  2013cites this paper
• Lessons that newborn screening in the USA can teach us about biobanking and large-scale genetic studies.

  2013cites this paper
• Maternal attitudes to newborn screening for fragile X syndrome

  2013cites this paper
• Parental Decision-Making and Acceptance of Newborn Bloodspot Screening: An Exploratory Study

  2013cites this paper
• Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK)

  2013cites this paper
• Guidance in Social and Ethical Issues Related to Clinical, Diagnostic Care and Novel Therapies for Hereditary Neuromuscular Rare Diseases: “Translating“ the Translational

  2013cites this paper
• Decision Making in Expanded Newborn Screening: The Case of Duchenne Muscular Dystrophy.

  2013cites this paper
• Krabbe Newborn Screening: The Issue of Informed Consent

  2013cites this paper
• What Research Ethics Should Learn from Genomics and Society Research: Lessons from the ELSI Congress of 2011

  2012cites this paper
• Evidence‐based path to newborn screening for duchenne muscular dystrophy

  2012cites this paper
• Newborn screening for lysosomal storage diseases: an ethical and policy analysis

  2012cites this paper
• Genomic sequencing in newborn screening programs.

  2012cites this paper
• Fabry disease: studies on diagnosis, screening and patients’ perspectives

  2012cites this paper
• Ethical Challenges in the Care of Children and Families Affected by Life-Limiting Neuromuscular Diseases

  2012cites this paper
• Clinic-Based Infant Screening for Duchenne Muscular Dystrophy: A Feasibility Study

  2012cites this paper
• The future role of genetic screening to detect newborns at risk of childhood-onset hearing loss

  2012cites this paper
• Informed Choice for Newborn Blood Spot Screening in the United Kingdom: A Survey of Parental Perceptions

  2012cites this paper
• Developing a policy for paediatric biobanks: principles for good practice

  2012cites this paper
• Newborn Screening for Fragile X Syndrome: Do We Care What Parents Think?

  2011cites this paper
• Parents' Decisions to Screen Newborns for FMR1 Gene Expansions in a Pilot Research Project

  2011cites this paper
• Expanding newborn screening for lysosomal disorders: opportunities and challenges.

  2011cites this paper
• PARENTAL RESPONSES TO NEWBORN SCREENING FOR GENETIC SUSCEPTIBILITY TO TYPE 1 DIABETES

  2011cites this paper
• Postnatal screening for Klinefelter syndrome: is there a rationale?

  2011cites this paper
• Health-care providers’ views on pursuing reproductive benefit through newborn screening: the case of sickle cell disorders

  2011cites this paper
• Single Gene Disease Risk

  2010cites this paper
• Developing a conjoint analysis survey of parental attitudes regarding voluntary newborn screening

  2010cites this paper
• Parental Attitudes toward Ethical and Social Issues Surrounding the Expansion of Newborn Screening Using New Technologies

  2010cites this paper
• Debating Clinical Utility

  2010cites this paper
• Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening

  2010cites this paper
• Duchenne Muscular Dystrophy: A 30-Year Population-Based Incidence Study

  2010cites this paper
• Knowledge or Understanding? Informed Choice in the Context of Newborn Bloodspot Screening

  2010cites this paper
• The Expansion of Newborn Screening In Israel: Ethical and Social Dimensions

  2009cites this paper
• Duchenne muscular dystrophy and reproductive decision-making : implications of newborn screening

  2009cites this paper
• Fragile X screening: Attitudes of genetic health professionals

  2009cites this paper
• Tandem Mass Spectrometry Newborn Screening and Its Impact on Inborn Errors of Metabolism

  2009cites this paper
• Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).

  2009cites this paper
• Supporting family adaptation to presymptomatic and "untreatable" conditions in an era of expanded newborn screening.

  2009cites this paper
• Ethical and Policy Issues in Newborn Screening: Historical, Current, and Future Developments

  2009cites this paper
• What's new in newborn screening?

  2008cites this paper
• Ethical, Legal, and Social Concerns About Expanded Newborn Screening: Fragile X Syndrome as a Prototype for Emerging Issues

  2008cites this paper
• Questioning the Need for Informed Consent: A Case Study of California's Experience with a Pilot Newborn Screening Research Project

  2007cites this paper
• Recommendations from Multi-disciplinary Focus Groups on Cascade Testing and Genetic Counseling for Fragile X-associated Disorders

  2007cites this paper
• The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.

  2007cites this paper
• Duchenne muscular dystrophy: issues in expanding newborn screening

  2007cites this paper